PPARG and neoplasm: The PIVENS trial demonstrated that pioglitazone treatment significantly reduced steatosis and inflammatory features such as hepatocellular ballooning in non-alcoholic steatohepatitis (NASH) patients.8 PPARγ agonists have also been shown to decrease inflammation and tumorigenesis in multiple tumor models, such as colon, thyroid and lung cancers.9